For example, in colon adenocarcinoma (COAD), bladder urothelial carcinoma (BLCA), and liver hepatocellular carcinoma (LIHC), the high expression of CDKN2A is correlated with poor prognosis in patients. Here, CDKN2A is linked to bladder transitional cell carcinoma.